Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503484 | 1.00 | TACR1 (0.33) | TACR1IDO1TDO2AOC3SLC6A2 | |
| SCHEMBL502893 | 0.84 | ADRB2 (0.36) | AOC3 | |
| SCHEMBL502774 | 0.84 | ADRB2 (0.36) | AOC3 | |
| SCHEMBL502775 | 0.84 | ADRB2 (0.36) | AOC3 | |
| SCHEMBL23215033 | 0.80 | IDO1 (0.35) | TACR1IDO1TDO2AOC3 | |
| SCHEMBL6124751 | 0.80 | IDO1 (0.35) | TACR1IDO1TDO2AOC3 | |
| SCHEMBL2524000 | 0.77 | GABBR2 (0.42) | IDO1TDO2AOC3 | |
| SCHEMBL503052 | 0.75 | TRPA1 (0.39) | TACR1IDO1TDO2AOC3SLC6A2 | |
| SCHEMBL503051 | 0.75 | TRPA1 (0.39) | TACR1IDO1TDO2AOC3SLC6A2 | |
| SCHEMBL503338 | 0.75 | TRPA1 (0.39) | TACR1IDO1TDO2AOC3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132136-B2 | Pharmaceutical combination | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | SEMINIS VEGETABLE SEEDS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | TACR1 10/4885IDO1 660/4885TDO2 1470/4885 |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | TACR1 10/4885IDO1 660/4885TDO2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.